In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa

The Kaohsiung Journal of Medical Sciences
Yen-Hsu ChenTyen-Po Chen

Abstract

Combination therapy has been recommended to treat Pseudomonas aeruginosa infections worldwide. The purpose of the present study was to determine the in vitro activities of piperacillin, cefepime, aztreonam, amikacin, and ciprofloxacin alone and in combination against 100 clinical isolates of P. aeruginosa from one medical center in southern Taiwan. The combination susceptibility assay was performed using the checkerboard technique. The percentage of resistance of P. aeruginosa to single agents in our study was relatively high for the Asia-Pacific area, except to aztreonam. Piperacillin plus amikacin exhibited the highest potential for synergy (59/100) in this study. Moreover, a high percentage of synergism was also noted with amikacin combined with cefepime (7/100) or aztreonam (16/100). The combination of two beta-lactams, such as cefepime with piperacillin, and aztreonam with cefepime or piperacillin, showed synergistic effects against some P. aeruginosa isolates. Although ciprofloxacin is a good anti-pseudomonal agent, a very low potential for synergy with other antibiotics was demonstrated in this study. No antagonism was exhibited by any combination in our study. Among piperacillin-resistant strains, there was synergy with...Continue Reading

References

Apr 1, 1981·Antimicrobial Agents and Chemotherapy·N A KuckM Forbes
Apr 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R C Spencer
Sep 1, 1996·Diagnostic Microbiology and Infectious Disease·J K PohlmanJ A Washington
Dec 24, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N TroilletY Carmeli
Jul 14, 1998·Antimicrobial Agents and Chemotherapy·P D ListerC C Sanders
May 21, 1999·Archives of Internal Medicine·Y CarmeliM H Samore
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C GalesR Ramphal
Mar 19, 2002·Emerging Infectious Diseases·Po-Ren HsuehKwen-Tay Luh
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds

❮ Previous
Next ❯

Citations

Dec 3, 2014·Advanced Drug Delivery Reviews·Benjamin D Brooks, Amanda E Brooks
Oct 14, 2014·Diagnostic Microbiology and Infectious Disease·Christine RahmeThomas P Lodise
Aug 14, 2009·FEMS Microbiology Letters·Anthony M GeorgePeter G Middleton
Jun 2, 2017·Biological & Pharmaceutical Bulletin·Graciela Pinto VitorinoMaría Rosa Mazzieri
Jul 28, 2006·Journal of Perinatology : Official Journal of the California Perinatal Association·E FakiogluB C Herold
Apr 9, 2021·Annals of the New York Academy of Sciences·Luke N YaegerLori L Burrows

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.